Reagents and consumables for Roche immunostainers
National Institutes of Health · Bethesda, MD
Why this score
Recently updated; but only 1 day left.
Solicitation # 75N98027R00020Updated Nov 16, 2026Scored Nov 17, 2026
Nov 30
Nov 30, 2026, 11:00 AM EST
Summary by RFP Detector
National Institutes of Health (National Institutes of Health NIDA), part of the Department of Health and Human Services, posted a sources sought notice titled “Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics” under solicitation number 75N98027R00020. It was posted on Nov 16, 2026. Responses are due Nov 30, 2026, 11:00 AM EST. It is classified under NAICS 325411 (Medicinal and Botanical Manufacturing) and product/service code AN11. No set-aside is listed. The place of performance is Bethesda, Maryland. The listed point of contact is Polina Klimenkova.
RFP Detector Score
Every RFP starts at 50. Each factor adds or subtracts points compared with a typical RFP; unknown data counts as neutral.
Starts at 50
No value published, and there isn't enough award history to estimate one. Scored as neutral.
Full and open competition.
8 other RFPs from National Institutes of Health on RFP Detector in the past 12 months; no award history found.
Sources sought (market research, not a bid): 13 days to respond (due Nov 30, 2026, 11:00 AM EST).
Documents not listed, named contact with email and phone, 456-word description.
Posted today.
50 + contributions = 67 (B, Strong)
Informational, not advice to bid or not bid. Score version 1.0.0, evaluated Nov 17, 2026.
Eligibility · Full and open competition
Full and open competition means the notice states no set-aside: any responsible business can respond, subject to the requirements in the notice.
Not stated in a form we could extract. See the official solicitation for requirements, evaluation criteria and submission steps.
From the official notice
Title: Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. The Government is especially interested in determining (1) the availability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition (5) commercial product and services availability. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. Background: The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) conducts translational research in the area of human therapeutics development by moving small molecule and biologic drug candidates forward in the drug development pipeline. Upon reaching predetermined milestones, TDB hands off clinical candidates to external partners to bring these novel therapies to patients. In addition to developing new candidate drugs, TDB seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial preclinical stage of drug development. The TDB model is to operate as a comprehensive small molecule and biologics drug development organization, moving therapeutic candidates through each phase of the preclinical development process until an Investigational New Drug (IND) application is filed with the US Food and Drug Administration (FDA). TDB conducts drug development as collaborations, with therapeutic candidates originating from academia, industry, non- profit foundations, or internally from NCATS and other NIH Institutes and Centers. TDB’s operational strategy is to combine the capabilities of in-house staff and collaborative partners with complementary support from contract research organizations (CROs). Each development program operates in a multi-disciplinary matrix team environment, with NCATS responsible for the overall planning and execution. Please see the attachment for more details.
No documents are listed for this notice.
Polina Klimenkova
PrimaryPoints of contact as published on the notice.
Sources Sought posted
Responses dueNext · in 13 days
Archive date on the official notice
Same NAICS group or Healthcare & Medical, nearby first, ranked by score.
National Institutes of Health · Bethesda, MD
Why this score
Recently updated; but only 1 day left.
Federal Prison System / Bureau of Prisons · Cumberland, MD
Why this score
79 days to respond, active buyer ($1.8B FY24–FY26); but small typical award (~$177K).
National Institutes of Health · Brooklyn, MD
Why this score
Small-business set-aside, posted today; but small typical award (~$52K).
National Institutes of Health · Bethesda, MD
Why this score
Posted today, clear, complete notice; but small typical award (~$85K).
National Institutes of Health · Bethesda, MD
Why this score
Clear, complete notice, active buyer ($4.4B FY24–FY26); but posted 777 days ago.
Health Resources and Services Administration · Rockville, MD
Why this score
Small-business set-aside, 1738 days to respond; but small typical award (~$25K).
RFP Detector Scores are informational.How we score →
68 open RFPs from this issuer and its offices.
National Institutes of Health
Why this score
Active buyer ($793M FY24–FY26), recently updated; but only less than a day left.
National Institutes of Health · Bethesda, MD
Why this score
Active buyer ($4.4B FY24–FY26), recently updated; but only less than a day left.
National Institutes of Health · Bethesda, MD
Why this score
Active buyer ($4.4B FY24–FY26), recently updated; but only less than a day left.
National Institutes of Health · Bethesda, MD
Why this score
Recently updated; but only 1 day left.
National Institutes of Health · Bethesda, MD
Why this score
Active buyer ($218M FY24–FY26), clear, complete notice; but only 1 day left.
National Institutes of Health · Bethesda, MD
Why this score
Full and open, active buyer ($113M FY24–FY26); but only 1 day left.
RFP Detector Scores are informational.How we score →
Official federal notice. Updated Nov 16, 2026.
Official solicitation:Sign in free to open the official solicitation
RFP Detector is an independent service and is not affiliated with any government agency. Scores are informational.
RFP Detector is not affiliated with the organization that issued this RFP. Always rely on the official notice and confirm every date and requirement with the issuer.